Quanterix (QTRX) AI Stock Analysis

• Market Cap: $259.94M
• Dividend Yield: N/A
• Average Volume (3M): 773.86K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.28
• Revenue Growth: 7.71%
• EPS Growth: -38.97%
• Country: US
• Employees: 471
• Sector: Healthcare
• Sector Strength: 40
• Industry: Medical - Devices
• EPS (TTM): -0.53
• Shares Outstanding: 38,854,877
• 10 Day Avg. Volume: 882,720
• 30 Day Avg. Volume: 773,857
• PEG Ratio: -0.08
• Price to Book (P/B): 1.43
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -8.54
• Enterprise Value/Market Cap: 0.84
• Enterprise Value/Revenue: 0.41
• Enterprise Value/Gross Profit: 2.78
• Enterprise Value/Ebitda: -1.14
• 1Y Price Target: $9.50
• Price Target Upside: 37.28% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

• Rating: 57 Neutral
• Price Target: $6.00 ▼(-13.29%Downside)

Quanterix's overall stock score is driven primarily by its growth potential and strategic initiatives, such as product launches and merger synergies. However, significant risks remain due to ongoing financial losses and valuation challenges. Positive technical momentum and corporate events provide some support, but profitability and cash flow improvements are crucial for future performance.

Positive Factors

Insider Confidence

Recent insider purchases could suggest these individuals believe the stock is undervalued.

Product Launches

New product launches and benefits from the Akoya acquisition should drive stronger performance and valuation levels higher for QTRX.

Negative Factors

Integration Risks

The acquisition adds integration risks to an already challenging macro backdrop and reduces cash flexibility for QTRX.

Macro Headwinds

Macro headwinds and continued NIH funding noise have led to relatively flat consumables and a significant sequential decrease in instrument revenue.

Market Competition

There are risks of QTRX falling behind in the Alzheimer's diagnostics market, with competitors already obtaining or planning FDA approvals.

Quanterix Business Overview & Revenue Model

Company Description

Quanterix Corporation is a life sciences company specializing in ultra-sensitive biomarker detection technology. The company operates primarily in the biotechnology and diagnostics sectors. Its flagship product is the Simoa (Single Molecule Array) platform, which enables researchers to detect and quantify proteins and other biomarkers in various sample types at significantly lower concentrations than traditional methods. Quanterix's technology is used in a wide range of applications, including neurology, oncology, and infectious diseases, providing critical insights for both research and clinical diagnostics.

How the Company Makes Money

Quanterix generates revenue through the sale of its Simoa platform, which includes instruments, consumables, and reagent kits essential for biomarker detection and analysis. The company also earns income from service agreements, offering customized assay development and sample testing services to pharmaceutical companies, academic institutions, and research organizations. Additionally, Quanterix partners with other companies and institutions to leverage its technology in clinical trials and research studies, providing a further revenue stream through collaborative agreements and licensing deals.

Quanterix Financial Statement Overview

Summary

Quanterix's financial performance shows mixed results. Revenue growth is evident, but the company struggles with profitability due to negative net income and EBIT margins. The balance sheet is strong with low debt, yet negative cash flows remain a concern, indicating the need for operational improvements.

Income Statement

The company has shown revenue growth over several years, but profitability is a concern with consistently negative net income and EBIT margins. Gross profit margin is relatively stable, but high operating losses impact overall performance.

Balance Sheet

The balance sheet is solid with a healthy equity base and low debt levels, as indicated by a low debt-to-equity ratio. However, the company is not yet generating positive returns on equity due to ongoing net losses.

Cash Flow

Operating cash flow remains negative, reflecting ongoing operational challenges. Free cash flow has shown some improvement but remains negative, indicating the company is not yet self-sustaining.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	135.29M	135.44M	122.37M	104.95M	110.56M	86.38M
Gross Profit	78.39M	81.12M	70.65M	46.24M	61.73M	48.18M
EBITDA	-59.16M	-44.26M	-38.09M	-65.73M	-53.24M	-27.27M
Net Income	-49.96M	-38.53M	-32.33M	-96.70M	-57.69M	-31.53M
Balance Sheet
Total Assets	396.51M	406.53M	425.01M	434.20M	501.53M	271.05M
Cash, Cash Equivalents and Short-Term Investments	266.88M	289.12M	321.32M	338.74M	396.46M	181.58M
Total Debt	36.41M	37.37M	41.46M	44.10M	21.89M	30.80M
Total Liabilities	80.12M	76.50M	78.08M	75.26M	60.58M	64.92M
Stockholders Equity	316.39M	330.04M	346.93M	358.94M	440.95M	206.13M
Cash Flow
Free Cash Flow	-33.01M	-38.53M	-22.69M	-60.00M	-61.52M	-27.30M
Operating Cash Flow	-28.89M	-35.16M	-18.90M	-48.27M	-47.91M	-23.36M
Investing Cash Flow	59.69M	-82.27M	-148.40M	-11.21M	-6.34M	-626.00K
Financing Cash Flow	-50.00K	456.00K	2.69M	2.31M	270.80M	96.24M

Quanterix Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 6.92
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For QTRX, the sentiment is Positive. The current price of 6.92 is above the 20-day moving average (MA) of 6.17, above the 50-day MA of 5.64, and below the 200-day MA of 9.00, indicating a neutral trend. The MACD of 0.33 indicates Negative momentum. The RSI at 64.18 is Neutral, neither overbought nor oversold. The STOCH value of 84.41 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for QTRX.

Quanterix Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ELMD	77 Outperform	$170.41M	25.46	16.56%	―	14.85%	64.96%
CERS	63 Neutral	$282.92M	―	-36.14%	―	13.06%	41.50%
Sector *	59 Neutral	£5.93B	9.05	-57.69%	4.70%	15.15%	-8.16%
QTRX	57 Neutral	$259.94M	―	-14.51%	―	7.71%	-38.97%
RCEL	55 Neutral	$136.67M	―	-407.50%	―	32.24%	-66.93%
LUNG	46 Neutral	$109.50M	―	-60.68%	―	19.84%	5.77%
ANIK	45 Neutral	$161.34M	―	-20.42%	―	-18.80%	26.16%

Quanterix Corporate Events

Quanterix Revises Deadlines for Stockholder Proposals

On June 26, 2025, Quanterix Corporation’s board announced that the 2025 Annual Meeting of Stockholders will be held virtually on September 23, 2025. Due to the meeting’s date being more than 30 days from the previous year’s meeting, deadlines for stockholder proposals and nominations have been revised, with new deadlines set for July 11 and July 25, 2025, to comply with SEC rules and the company’s bylaws.

The most recent analyst rating on (QTRX) stock is a Hold with a $17.00 price target. To see the full list of analyst forecasts on Quanterix stock, see the QTRX Stock Forecast page.

Quanterix Approves Cost-Reduction Plan Amidst Strategic Moves

On May 7, 2025, Quanterix‘s Board of Directors approved a cost-reduction plan to save $15 million in 2025, with annualized savings of $30 million. This includes a significant reduction in workforce, expected to be completed by the end of the second quarter of 2025. Additionally, Quanterix announced a strategic move to integrate its Simoa® ONE assay kits with over 20,000 flow cytometers globally, enhancing its market reach and reducing the need for new equipment purchases. The company also reported a net loss for the first quarter of 2025 but is implementing measures to achieve positive cash flow by 2026, including a merger with Akoya Biosciences, expected to close in June 2025.

The most recent analyst rating on (QTRX) stock is a Hold with a $17.00 price target. To see the full list of analyst forecasts on Quanterix stock, see the QTRX Stock Forecast page.

Quanterix Revises Merger Terms with Akoya Biosciences

On April 28, 2025, Quanterix Corporation announced an amended merger agreement with Akoya Biosciences, revising the terms of their previously announced merger. Under the new terms, Quanterix will issue fewer shares and pay $20 million in cash to Akoya shareholders, with Quanterix shareholders owning 84% of the combined entity. This strategic move aims to create value for shareholders and leverage combined resources to drive synergies and expedite profitability. The merger is expected to close in the second quarter of 2025, pending Akoya shareholder approval and other customary conditions.